The interest rate on borrowings. [Refer: Borrowings]

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name IFRS
-Number 7
-IssueDate 2023-01-01
-Paragraph 7
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_BorrowingsInterestRate
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2023-01-01
-Paragraph 17
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 27
-IssueDate 2023-01-01
-Paragraph 16
-Subparagraph b
-Clause iii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph 19B
-Subparagraph c
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix:	ifrs-full_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The period over which debt instrument were converted in to ordinary shares.

+ References

No definition available.

+ Details

Name:	prqr_DebtInstrumentConversionTerm
Namespace Prefix:	prqr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain (loss) on waiver of convertible debt

+ References

No definition available.

+ Details

Name:	prqr_GainLossOnWaiverOfConvertibleDebt
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of gains (losses) on derecognition of financial liabilities.

+ References

No definition available.

+ Details

Name:	prqr_GainLossesOnDerecognitionOfFinancialLiabilities
Namespace Prefix:	prqr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Period upon which unconverted loans become payable on demand

+ References

No definition available.

+ Details

Name:	prqr_PeriodUponWhichUnconvertedLoansBecomePayableOnDemand
Namespace Prefix:	prqr_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	ifrs-full_SignificantInvestmentsInSubsidiariesAxis=prqr_AmylonTherapeuticsB.vMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_BorrowingsByNameAxis=prqr_ConvertibleLoansAmylonTherapeuticsB.v.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Results Related to Derecognition of Financial Liabilities (Details) - EUR (€) € in Thousands	3 Months Ended	9 Months Ended		24 Months Ended
	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2019
Disclosure of detailed information about borrowings [line items]
Gain on waivers of Amylon convertible loans			€ 1,866
Total results related to derecognition of financial liabilities	€ 1,357		1,866
Amylon Therapeutics B.V
Disclosure of detailed information about borrowings [line items]
Proportion of ownership interest in subsidiary				80.00%
Convertible loans Amylon Therapeutics B.V.
Disclosure of detailed information about borrowings [line items]
Gain on waivers of Amylon convertible loans		€ 0	€ 1,866
Borrowings, interest rate				8.00%
Convertible loans Amylon Therapeutics B.V. \| Minimum
Disclosure of detailed information about borrowings [line items]
Period upon which unconverted loans become payable on demand				24 months
Convertible loans Amylon Therapeutics B.V. \| Maximum
Disclosure of detailed information about borrowings [line items]
Debt Instrument Conversion Term				36 months
Period upon which unconverted loans become payable on demand				36 months